IP Library Granted Patent US 12685782
Granted Patent B2
US 12685782 · App. 19/253,824 · Granted Jul 21, 2026

Bifunctional degraders for the treatment of Graves' disease

Inventors: Anna Bunin (Queens, NY); Seong Lee (West Haven, CT); Kathren Croce (New Haven, CT); Miranda L. Simes (Somerville, MA); Edward Deramon (Hamden, CT); Mariano Oppikofer (Stamford, CT)
Assignee: Biohaven Therapeutics Ltd.
A61K47/6849A61K47/6803C07K16/2869C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12685782
App. No.
19/253,824
Granted
Jul 21, 2026
Kind
B2
Abstract

A composition of matter including an anti-TSH receptor autoantibody-binding moiety, a cellular receptor-binding moiety that binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting the anti-TSH receptor autoantibody-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing anti-TSH receptor autoantibody from a patient or subject, such as a Graves' disease patient.

Claims (33)

1 . A composition of matter having Formula (I):

wherein,

each {circle around (A)} is a moiety having SEQ ID NO: 7 or a TSHR antigen protein thereof, wherein the TSHR antigen protein amino acid sequence has 95% sequence identity with SEQ ID NO: 7, wherein the amino acid sequence of the TSHR antigen protein has the same numbering as SEQ ID NO: 7 according to the EU numbering scheme, wherein the differences in amino acid sequence between the sequence of SEQ ID NO: 7 and sequence of the TSHR antigen protein are due only to conservative amino acid substitutions, and wherein the TSHR antigen protein is capable of binding to anti-TSH receptor autoantibody;

each

 is a linking moiety connecting {circle around (A)} and

each

 is a peptide moiety having SEQ ID NO: 8, wherein the moieties

 are linked together via two disulfide bridges

 as shown in Formula (II), wherein one disulfide bridge links cysteine residues located in position 11 of SEQ ID NO: 8 of each moiety

 and wherein the other disulfide bridge links cysteine residues located in position 14 of SEQ ID NO: 8 of each moiety

each

 is a linker moiety connecting

 and {circle around (E)} wherein each

 is connected to

 via a side chain amino group of a lysine residue of

 to form

 and

each {circle around (E)} is an asialoglycoprotein receptor (“ASGPR”) binding moiety comprising an N-acetyl-D-galactosamine (“GalNAc”) group having Formula (II):

2 . The composition of matter of claim 1 , wherein

 each chemical bond or a peptide connecting moiety comprising an amino acid selected from the group consisting of G, E, L, P, Q, S, and T.

3 . The composition of matter of claim 1 , wherein each

comprises a moiety selected from the group consisting of:

wherein,

X 2 are independently CH 2 , O, S, NR 4 , C(O), S(O), S(O) 2 , S(O) 2 O, OS(O) 2 , or OS(O) 2 O;

X 3 are independently O, S, NR 4 , wherein R 4 is H or a C 1 -C 3 alkyl; and

k and n are independently 1 to 25.

4 . The composition of matter of claim 1 , wherein each {circle around (E)} comprises a moiety selected from the group consisting of:

wherein,

X 2 are independently CH 2 , O, S, NR 4 , C(O), S(O), S(O) 2 , S(O) 2 O, OS(O) 2 , or OS(O) 2 O;

X 3 are independently O, S, NR 4 , wherein R 4 is H or a C 1 -C 3 alkyl; and

k and n are independently 1 to 25.

5 . The composition of matter of claim 1 , wherein each

comprises a group having Formula (IV) or Formula (V):